AAPS National Biotechnology Conference (NBC) 2023

AAPS National Biotechnology Conference (NBC) 2023
June 6, 2023 BioData Solutions

AAPS National Biotechnology Conference (NBC) 2023

We are all geared up for NBC 2023. Join us for a co-sponsored discussion with KCAS “Panel Discussion: Common Challenges in Bioanalytical Assay Validation/Development in CGTP,” a demonstration of the beta version of an automated software tool for determining cut point using Random Effects Model for your CGTP datasets, and some Ariadne and BioData swag at booth #213!

April 23-26, 2023 | Philadelphia, PA
Visit Us at Booth #213

Common Challenges in Bioanalytical Assay Validation/Development in CGTP

April 24, 2023 | 2:30 pm – 3:15 pm ET
Venue: Learning Lab, Franklin Hall, Marriott Downtown Philadelphia

As BioData Solutions and Ariadne Software are merging, we will be showcasing BioData’s services and Ariadne’s software modules at the booth. Join us at booth #213 to demo our beta version for a more accurate Cut Point determination using Random Effects Model to address the variance in population without the need to remove outliers. It will certainly make statistical analysis for your cell and gene therapy data quick and easy… And did we mention the analysis takes less than a minute??!!

Carrie Vyhlidal, PhD; Associate Director, KCAS Bioanalytical and Biomarker Services

Stephanie Pasas-Farmer, PhD; President and Principal Consultant; BioData Solutions

Lillian Falese; Associate Director, Bioanalytical Development; Spirovant Sciences, Inc.
Kelly Colletti, PhD, MBA; Director, Preclinical Bioanalytics; Beam Therapeutics Inc.
David Kuhel, PhD; Senior Vice President and President at PPD Clinical Research
Brian D. Bower, PhD; Scientist III, Gene and Cell Therapy; BioAgilytix Labs

With the growing emergence of cell and gene therapies to serve as preventive and curative options for patient care, we need to address some common challenges in their development. Through case studies, we will use our panel to walk us through issues such as transition of assays from CLIA to FDA laboratories, selection of more appropriate positive controls and housekeeping genes, as well as well-defined acceptance criteria for qPCR and RT-qPCR.